Nurix Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Good afternoon, everyone. My name is Gil Blum, and I'm a senior biotech analyst here at Needham and Company, covering immuno-oncology and the gene therapy subsectors. It is my pleasure to have with me today Nurix's management team, including Dr. Arthur Sands and Robert Brown, EVP of Clinical Development. As a reminder, any of you who are watching through our conference portal, are able to submit questions via the Ask a Question box below the video feed window. So just to dive in here, Arthur, can you provide some introductory remarks for Nurix and its protein degradation technology?
Sure, Gil, and thanks for having us and to the entire Needham team. We look forward to someday being in person again. Before I provide some introduction, I should mention we will be making certain forward-looking statements, and I refer everyone to our filings with the SEC regarding risk factors. So we are focused on targeted protein modulation, which is inclusive of both targeted
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |